Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation....
Publications
3 shownRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patient...
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding. (ClinicalTrials.gov number, NCT00361894.)
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 5,884
- Institution
- Bayer (Germany)
External Links
Identifiers
- ORCID
- 0000-0003-1366-7958
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.